The endogenous regulation of the cytokine disbalance in humans subjected to simulated spaceflight environment

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 7, 2006, Pages 15-20

  Uchakin, P N ^a   Uchakina, O N ^a   Morukov, B V ^a   Larina, I M ^a   Bogdanova, N B ^a   Mezentseva, M V ^a   Tobin, B V ^a   Yershov, F I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748095506     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Taylor G. R., Dardano J. R. Human cellular immune responsiveness following space flight. Aviat. Space Environ. Med. 1983; 54 (12, pt 2): S55-S59.
2. Meehan R. T., Neale L. S., Kraus E. T. et al. Alteration in human mononuclear leucocytes following space flight. Immunology. 1992; 76 (3): 491-497.
3. Sonnenfeld G., Mandel A. D., Konstantinova I. V. et al. Effects of spaceflight on levels and activity of immune cells. Aviat Space Environ. Med. 1990; 61 (7): 648-653.
4. Sonnenfeld G., Mandel A. D., Konstantinova I. V. et al. Spaceflight alters immune cell function and distribution. J. Appl. Physiol. 1992; 73 (2, suppl.): 191S-195S.
5. Fuchs B. M. Countermeasures for ameliorating in-flight immune dysfunction. J. Leukoc. Biol. 1993; 54 (3): 245-252.
6. Chapes S. K., Morrison D. R., Guikema J. A. et al. Cytokine secretion by immune cells in space. J. Leukoc.Biol. 1992; 52 (1): 104-110.
7. Konstantinova I. V., Rykova M. P., Lesnyak A. T. et al. Immune changes during long-duration missions. J. Leukoc.Biol. 1993; 54 (3): 189-201.
8. Lesnyak A. T., Sonnenfeld G., Avery L. et al. Effect of SLS-2 spaceflight on immunologic parameters of rats. J. Appl. Physiol. 1996; 81 (1): 178-182.
9. Manie S., Konstantinova I. V., Breittmayer J. P. et al. Effects of long duration spaceflight on human T lymphocyte and monocyte activity. Aviat. Space Environ. Med. 1991; 62 (12): 1153-1158.
10. Gmunder F. K., Konstantinova I. V., Cogoli A. et al. Cellular immunity in cosmonauts during long duration spaceflight on board the orbital MIR station. Aviat. Space Environ. Med. 1994; 65 (5): 419-423.
11. Leach C. S. Fluid control mechanisms in weightlessness. Aviat. Space Environ. Med. 1987; 58 (9, pt 2): A74-A79.
12. Meehan R., Whilson P., Sams C. The role of psychoneuroendocrine factors on spaceflight-induced immunological alterations. J. Leukoc. Biol. 1993; 54 (3): 236-244.
13. Macho L., Jezov D., Jurcovicov J. et al. Effect of space flight on the development of endocrine functions in rats. Endocr. Regul. 1993; 27 (1); 17-22.
14. Sonnenfeld G., Miller E. S. The role of cytokines in immune changes induced by spaceflight. J. Leukoc. Biol. 1993; 54 (3): 253-258.
15. Tigranjan R. A., Haase H., Voronin L. I. et al. Results of endocrinologic studies of the 3d international crew of the scientific orbital station complex: Soyuz 29 - Salyut 6 - Soyuz 31 (joint space flight enterprise of the USSR - GDR). 3. Corticosteroid excretion in urine. Endokrinologie 1982; 80 (1): 42-47.
16. Tipton C. M., Greemlead J. E., Jackson C. G. Neuroendocrine and immune system responses with spaceflights. Med. Sci. Sports Exerc. 1996; 28 (8): 988-998.
17. Stowe R. P., Pierson D. L., Barrett A. D. Elevated stress hormone levels relate to Epstein-Barr virus reactivation in astronauts. Psychosom. Med. 2001; 63 (6): 891-895.
18. Hennig J., Netter P. Local immunocompetence and salivary cortisol in confinement. Adv. Space Biol. Med. 1996; 5: 115-132.
19. Maillet A., Gunga H. C., Normand S. et al. Effects of a 60-day confinement on the blood pressure, hormonal responses and body fluids of a mixed crew. J. Gravit. Physiol. 1998; 5 (2): 55-64.
20. Maillet A., Gunga H. C., Gauquelin G. et al. Effects of 28-day isolation (ESA- 1SEMSI'90) on blood pressure and blood volume regulating hormones. Aviat. Space Environ. Med. 1993; 64 (4): 287-294.
21. Schmitt D. A., Schaffar L. European isolation and confinement study. Confinement and immune function. Adv. Space Biol. Med. 1993; 3: 229-235.
22. Mosmann T. R., Cherwinski H., Bond M. W. et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986; 136 (7): 2348-2357.
23. Del Prete G., Ricci M., Romagnani S. T cells, IgE antibodies, cytokines and allergic inflammation. Allerg Immunol. (Paris) 1991; 23 (6): 239-243.
24. Haanen J. B., de Waal Malefijt R., Res P. C. et al. Selection of a human T helper type 1-like T cell subset by mycobacteria. J. Exp. Med. 1991; 174 (3): 583-592.
25. Jaber J., Murin J., Kinova S. et al. The role of infection and inflammation in the pathogenesis of atherosclerosis. Vnitr. Lek. 2002; 48 (7): 657-666.
26. Kanaly S. T., Hines S. A., Palmer G. H. Cytokine modulation alters pulmonary clearance of Rhodococcus equi and development of granulomatous pneumonia. Infect. and Immun. 1995; 63 (8): 3037-3041.
27. Welling K. Acute respiratory distress syndrome. Pathogenesis and therapy of acute pulmonary failure. Ugeskr. Laeg. 1996; 158 (25): 3593-3600.
28. Colavita A. M., Reinach A. J., Peters S. P. Contributing factors to the pathobiology of asthma. The Th1/Th2 paradigm. Clin. Chest Med. 2000; 21 (2): 263-277.
29. Maes M., Bonaccorso S., Marino V. et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol. Psychiatry 2001; 6 (4): 475-480.
30. Bonaccorso S., Puzella A., Marino K et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001; 105 (1-2): 45-55.
31. Barber A. E., Coyle S. M., Marano M. A. et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J. Immunol. 1993; 150 (5): 1999-2006.
32. Paliogianni F., Ahuja S. S., Balow J. P. et al. Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor. J. Immunol. 1993; 151 (8): 4081-4089.
33. Elenkov I. J., Chrousos G. P. Stress hormones, Th1/Th2 patterns, Pro/Anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 1999; 10 (9): 359-368.
34. Benyoucef S., Hober D., Shen L. et al. Production of TNFalpha and IL-6 by activated whole blood from HIV-1 infected patients detected by a one-stage procedure: relationship with the phenotype of HIV-1 isolates. Microbiol. and Immunol. 1997; 41 (12): 939-946.
35. Benyoucef S., Lion G., Gerard Y. et al. Imbalance in cytokine production by whole blood related to presence of cytopathogenic HIV-1 strains in HIV-1-infected patients. Infection 1998; 26 (2): 109-112.
36. Bienvenu J., Doche C., Gutowski M. C. et al. Production of proinflammatory cytokines and cytokines involved in the Th1/ Th2 balance is modulated by pentoxifylline. J. Cardiovasc. Pharmacol. 1995; 25 (suppl. 2): S80-S84.
37. De Groote D., Zangerle P. F., Gevaert Y. et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PB-MC stimulation. Cytokine 1992; 4 (3): 239-248.
38. Uchakin P. N., Tobin B. W., Morukov B. V. et al. Type 1 vs. Type 2 cytokine secretion in vitro and its regulation by hydrocortisone in humans subjected to 120-day anti-orthostatic bed-rest regime. J. Gravit. Physiol. 2002; 9 (2): 71-82.
39. Clerici M., Balotta C., Salvaggio A. et al. Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood 1996; 88 (2): 574-579.
40. Niessner A., Ziegler S., Slany J. et al. Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids? Eur. J. Endocrinol. 2003; 149 (6): 555-559.
41. Heitkamp H. C., Huber W., Scheib K. beta-Endorphin and adrenocorticotrophin after incremental exercise and marathon running-female responses. Eur. J. Appl. Physiol. Occup. Physiol. 1996; 72 (5-6): 417-424.
42. Cook N. J., Ng A., Read G. F. et al. Salivary Cortisol for monitoring adrenal activity during marathon runs. Horm. Res. 1987; 25 (1): 18-23.
43. Cook N. J., Read G. F., Walker R. F. et al. Changes in adrenal and testicular activity monitored by salivary sampling in males throughout marathon runs. Eur. J. Appl. Physiol. Occup. Physiol. 1986; 55 (6): 634-638.
44. Semple C. G., Thomson J. A., Beastall G. H. Endocrine responses to marathon running. Br. J. Sports Med. 1985; 19 (3): 148-151.
45. Davies D. M. Sixty days in a submarine: the pathophysiological and metabolic cost. J. Roy. Coll. Physicians Lond. 1973; 7 (2): 132-144.
46. Christmas S. E., Meager A., Moore M. Production of Interferon and tumour necrosis factor by cloned human natural cytotoxic lymphocytes and T cells. Clin. Exp. Immunol. 1987; 69 (2): 441-450.
47. Solerte S. B., Cravello L., Ferrari E. et al. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000; 917: 331-340.
48. Mallone R., Funaro A., Zubiaur M. et al. Signaling through CD38 induces NK cell activation. Int. Immunol. 2001; 13 (4): 397-409.
49. Korbel D. S., Finney O. C., Riley E. M. Natural killer cells and innate immunity to protozoan pathogens. Int. J. Parasitol. 2004; 34 (13-14): 1517-1528.
50. Chang C. C., Wright A., Punnonen J. Monocyte-derived CD1a+ and CD1a- dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J. Immunol. 2000; 165 (7): 3584-3591.
51. Rivas-Carvalho A., Meraz-Rios M. A., Santos-Argumedo L. et al. CD16+ human monocyte-derived dendritic cells matured with different and unrelated stimuli promote similar allogeneic Th2 responses: regulation by pro- and anti-inflammatory cytokines. Int. Immunol. 2004; 16 (9): 1251-1263.
52. Wagner H. J., Bollard C. M., Vigouroux S. et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T sells. Cancer Gene Ther. 2004; 11 (2): 81-91.
53. Spruance S. L., Evans T. G., McKeough M. B. et al. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res. 1995; 28 (1): 39-55.
54. Romani L. Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr. Opin. Microbiol. 1999; 2 (4): 363-367.
55. Hukkanen V., Broberg E., Salmi A. et al. Cytokines in experimental herpes simplex virus infection. Int. Rev. Immunol. 2002; 21 (4-5): 355-371.
56. Babiuk S., Skowronski D. M., De Serres G. et al. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J. Med. Virol. 2004; 72 (1): 138-142.
57. Mack V. E., McCarter M. D., Naama H. A. et al. Candida infection following severe trauma exacerbates Th2 cytokines and increases mortality. J. Surg. Res. 1997; 69 (2): 399-407.
58. Ohshima K., Karube K., Hamasaki M. et al. Differential chemokine, chemokine receptor and cytokine expression in Epstein-Barr virus-associated lymphoproliferative diseases. Leukemia and Lymphoma 2003; 44 (8): 1367-1378.